[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Liu FS, Jan YJ, Lai CR, Twu NF, Lu CH, Hung MJ, Hsieh YT, Chiou LC: Expression analysis of apoptosis-related markers TP53, BCL-2, BAX and c-MYC in female genital tract sarcomas. J Chin Med Assoc; 2008 Dec;71(12):628-34
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression analysis of apoptosis-related markers TP53, BCL-2, BAX and c-MYC in female genital tract sarcomas.
  • BACKGROUND: Most female genital tract sarcomas are highly malignant and fatal.
  • Their aggressive growth pattern and poor response to chemotherapy are the major causes of death.
  • METHODS: Paraffin blocks of female genital tract sarcoma tissue from 54 patients were obtained after pathology review.
  • Associations between expression of the apoptotic markers and tumor stage as well as outcome were also analyzed.
  • RESULTS: We found that all 4 of the apoptosis-related markers were frequently expressed in female genital tract sarcomas.
  • CONCLUSION: Since changes in TP53, BCL-2, BAX and c-MYC frequently occur in female genital tract sarcomas, deregulation of apoptosis appears to be involved in the pathogenesis of this group of tumors.
  • [MeSH-major] Genital Neoplasms, Female / chemistry. Proto-Oncogene Proteins c-bcl-2 / analysis. Proto-Oncogene Proteins c-myc / analysis. Sarcoma / chemistry. Tumor Suppressor Protein p53 / analysis. bcl-2-Associated X Protein / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19114327.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-myc; 0 / Tumor Suppressor Protein p53; 0 / bcl-2-Associated X Protein
  •  go-up   go-down


2. Di Cocco B, Salesi N, Fabi A, Nardoni C, Ferretti G, Bossone G, Ciccarese M, Savarese A, Vecchione A, Cognetti F: Alfa-epoietin and anaemia in gynaecological cancer. Anticancer Res; 2004 Mar-Apr;24(2C):1287-92
MedlinePlus Health Information. consumer health - Anemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence and severity of anaemia in gynaecological cancer patients depends on several factors including age, histology and tumor stage, site of neoplasm and treatment.
  • At present, two principal opinions are available for the management of chronic anaemia in cancer patients: blood transfusions and treatment with recombinant human Erythropoietin (rHuEPO).
  • Clinical studies showed that rHuEPO can ameliorate chronic and chemotherapy-induced anaemia and reduce transfusions in patients with various malignant diseases.
  • [MeSH-major] Anemia / drug therapy. Erythropoietin / therapeutic use. Genital Neoplasms, Female / blood
  • [MeSH-minor] Blood Transfusion. Clinical Trials as Topic. Female. Humans. Quality of Life. Recombinant Proteins

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15154662.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Recombinant Proteins; 11096-26-7 / Erythropoietin
  • [Number-of-references] 31
  •  go-up   go-down


3. Jiang T, Chen N, Zhao F, Wang XJ, Kong B, Zheng W, Zhang DD: High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res; 2010 Jul 1;70(13):5486-96
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High levels of Nrf2 determine chemoresistance in type II endometrial cancer.
  • Type II endometrial cancer, which mainly presents as serous and clear cell types, has proved to be the most malignant and recurrent carcinoma among various female genital malignancies.
  • Nrf2 is constitutively upregulated in several types of human cancer tissues and cancer cell lines.
  • Furthermore, inhibition of Nrf2 expression sensitizes cancer cells to chemotherapeutic drugs.
  • In this study, the constitutive level of Nrf2 was compared in different types of human endometrial tumors.
  • Silencing of Nrf2 rendered SPEC-2 cells more susceptible to chemotherapeutic drugs, whereas it had a limited effect on Ishikawa cells.
  • Inhibition of Nrf2 expression by overexpressing Keap1 sensitized SPEC-2 cells or SPEC-2-derived xenografts to chemotherapeutic treatments using both cell culture and severe combined immunodeficient mouse models.
  • Collectively, we provide a molecular basis for the use of Nrf2 inhibitors to increase the efficacy of chemotherapeutic drugs and to combat chemoresistance, the biggest obstacle in chemotherapy.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AACR.
  • [Cites] Mod Pathol. 2000 Mar;13(3):295-308 [10757340.001]
  • [Cites] Trends Biochem Sci. 2009 Apr;34(4):176-88 [19321346.001]
  • [Cites] Am J Respir Cell Mol Biol. 2002 Feb;26(2):175-82 [11804867.001]
  • [Cites] Nat Rev Cancer. 2003 Oct;3(10):768-80 [14570043.001]
  • [Cites] Mol Cell Biol. 2004 Aug;24(16):7130-9 [15282312.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] In Vitro Cell Dev Biol. 1990 Jul;26(7):701-8 [1696575.001]
  • [Cites] Anticancer Res. 1996 Mar-Apr;16(2):899-904 [8687148.001]
  • [Cites] Genes Dev. 1999 Jan 1;13(1):76-86 [9887101.001]
  • [Cites] J Clin Invest. 2004 Nov;114(9):1248-59 [15520857.001]
  • [Cites] Mol Cell Biol. 2004 Dec;24(24):10941-53 [15572695.001]
  • [Cites] J Exp Med. 2005 Jul 4;202(1):47-59 [15998787.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2605-13 [16284385.001]
  • [Cites] Mutat Res. 2005 Dec 11;591(1-2):93-102 [16054659.001]
  • [Cites] Mol Cell. 2006 Mar 3;21(5):689-700 [16507366.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4783-91 [17028294.001]
  • [Cites] PLoS Med. 2006 Oct;3(10):e420 [17020408.001]
  • [Cites] Drug Metab Rev. 2006;38(4):769-89 [17145701.001]
  • [Cites] Neurotoxicology. 2006 Dec;27(6):1094-100 [16959318.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2007;47:89-116 [16968214.001]
  • [Cites] Mol Cancer Ther. 2007 Jan;6(1):154-62 [17237276.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Nov 3;362(4):816-21 [17822677.001]
  • [Cites] Endocr Relat Cancer. 2009 Jun;16(2):363-80 [19190080.001]
  • [Cites] Toxicol Appl Pharmacol. 2009 Jun 15;237(3):267-80 [19303893.001]
  • [Cites] Mol Cell. 2009 Jun 26;34(6):663-73 [19560419.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Carcinogenesis. 2009 Sep;30(9):1571-80 [19608619.001]
  • [Cites] Toxicol Appl Pharmacol. 2009 Oct 1;240(1):8-14 [19538980.001]
  • [Cites] Eur J Pharmacol. 2009 Oct 12;620(1-3):138-44 [19698707.001]
  • [Cites] Free Radic Biol Med. 2009 Dec 1;47(11):1619-31 [19751820.001]
  • [Cites] J Pathol. 2010 Mar;220(4):446-51 [19967722.001]
  • [Cites] Diabetes. 2010 Apr;59(4):850-60 [20103708.001]
  • [Cites] Curr Opin Obstet Gynecol. 2008 Feb;20(1):26-33 [18197002.001]
  • [Cites] Cancer Lett. 2008 Feb 18;260(1-2):96-108 [18036733.001]
  • [Cites] Carcinogenesis. 2008 Jun;29(6):1235-43 [18413364.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7975-84 [18829555.001]
  • [Cites] Planta Med. 2008 Oct;74(13):1540-7 [18937168.001]
  • [Cites] J Obstet Gynaecol Res. 2008 Oct;34(5):776-83 [18958927.001]
  • [Cites] Pharmacol Res. 2008 Nov-Dec;58(5-6):262-70 [18838122.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3410-5 [11248092.001]
  • (PMID = 20530669.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA23074; United States / NCI NIH HHS / CA / P30 CA023074; United States / NIEHS NIH HHS / ES / ES015010-04; United States / NIEHS NIH HHS / ES / R01 ES015010-04; United States / NIEHS NIH HHS / ES / ES015010; United States / NIEHS NIH HHS / ES / R01 ES015010
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / KEAP1 protein, human; 0 / NF-E2-Related Factor 2; 0 / NFE2L2 protein, human; 0 / RNA, Messenger; 0 / RNA, Small Interfering; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ NIHMS203767; NLM/ PMC2896449
  •  go-up   go-down


Advertisement
4. Canavan TP, Doshi NR: Cervical cancer. Am Fam Physician; 2000 Mar 1;61(5):1369-76
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cervical cancer is the second most common type of cancer in women worldwide, after breast cancer.
  • A preponderance of evidence supports a causal link between human papillomavirus infection and cervical neoplasia.
  • The presence of high-risk human papillomavirus genital subtypes increases the risk of malignant transformation.
  • Widespread use of the Papanicolaou smear has dramatically reduced the incidence of cervical cancer in developed countries.
  • Advanced metastatic disease may respond to radiation therapy and concurrent chemotherapy.
  • Protein markers for detection of recurrence and vaccines for prevention of cervical cancer are under investigation.
  • [MeSH-major] Papillomaviridae. Papillomavirus Infections / complications. Tumor Virus Infections / complications. Uterine Cervical Neoplasms
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Female. Humans. Mass Screening. Neoplasm Staging. Pregnancy. Pregnancy Complications, Neoplastic / diagnosis. Pregnancy Complications, Neoplastic / therapy. Prognosis


5. An JS, Wu LY, Li N, Li B, Yu GZ, Liu LY: [Clinical analysis of 42 cases of primary malignant melanoma in female genital tract]. Zhonghua Fu Chan Ke Za Zhi; 2007 May;42(5):320-4
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 42 cases of primary malignant melanoma in female genital tract].
  • OBJECTIVE: To analyze the clinical characteristics, diagnosis, treatment and prognosis of primary malignant melanoma in female genital tract.
  • METHODS: The clinical data of 42 patients of primary malignant melanoma in female genital tract were reviewed.
  • In the 40 patients who received surgery, univariate analysis showed that the adjuvant chemotherapy improved the recurrence-free survival and the overall survival significantly (P < 0.05), and the other factors including radical surgery, regional lymphadenectomy, biotherapy and radiotherapy did not affect prognosis (P > 0.05).
  • Compared with chemotherapy, biochemotherapy did not improve prognosis significantly (P > 0.05).
  • CONCLUSIONS: Biopsy for the malignant melanoma in female genital tract has high misdiagnosis rate.
  • Surgery plays an important role in treatment, while the adjuvant chemotherapy could improve survival effectively.
  • [MeSH-major] Genital Neoplasms, Female / diagnosis. Genital Neoplasms, Female / therapy. Melanoma / diagnosis. Melanoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Immunohistochemistry. Lymph Node Excision. Melanoma-Specific Antigens. Middle Aged. Neoplasm Proteins / analysis. Neoplasm Staging. Prognosis. Radiotherapy. Retrospective Studies. S100 Proteins / analysis. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / therapy. Vaginal Neoplasms / diagnosis. Vaginal Neoplasms / metabolism. Vaginal Neoplasms / therapy. Vulvar Neoplasms / diagnosis. Vulvar Neoplasms / metabolism. Vulvar Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17673044.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / S100 Proteins
  •  go-up   go-down


6. Mundhenke C, Bauerschlag D, Fischer D, Friedrich M, Maass N: [Malignant tumors of the uterus]. Ther Umsch; 2007 Jul;64(7):381-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant tumors of the uterus].
  • [Transliterated title] Maligne Tumoren des Uterus.
  • Malignant uterine tumors are responsible for up to 9% of all new cancer cases and for 4.5% of all cancer related deaths in women.
  • Endometrial cancers are typically found in elderly women and are > 70% hormone sensitive (type I), type II is often less differentiated and not hormone sensitive.
  • Therapy of choice is the stage related radical hysterectomy (incl. lymphnode dissection).
  • Postoperatively and at progressive stages endocrine and radiation therapies can be useful.
  • Chemotherapy is only useful in not hormone sensitive and in progressive tumors.
  • These often aggressive tumors are hardly responding to systemic and radiation therapy.
  • Therefore radical tumor surgery plays the main therapeutic role.
  • Important co-factors for carcinogenesis are tobacco smoking, an immunodeficiency and chronic genital infections of other causes.
  • Many tumors are detected in early tumor stages.
  • Preoperatively diagnostic procedures are performed to examine local and distant tumor growth.
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Cervix Uteri / pathology. Combined Modality Therapy. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / epidemiology. Endometrial Neoplasms / pathology. Endometrial Neoplasms / radiotherapy. Endometrial Neoplasms / surgery. Endometrium / pathology. Female. Humans. Hysterectomy. Hysteroscopy. Lymph Node Excision. Middle Aged. Neoplasm Staging. Postoperative Care. Risk Factors. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / epidemiology. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / radiotherapy. Uterine Cervical Neoplasms / surgery. Uterus / pathology

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17948755.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 36
  •  go-up   go-down


7. Matsuura Y, Kitajima M, Hachisuga T, Tanimoto A, Okura N, Kihara I: Malignant mixed müllerian tumor with malignant neuroectodermal components (teratoid carcinosarcoma) of the ovary: Report of a case with clinicopathologic findings. J Obstet Gynaecol Res; 2010 Aug;36(4):907-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed müllerian tumor with malignant neuroectodermal components (teratoid carcinosarcoma) of the ovary: Report of a case with clinicopathologic findings.
  • Malignant mixed müllerian tumor (MMMT) or carcinosarcoma of the female genital tract is a rare neoplasm.
  • Malignant ovarian tumor composed of müllerian epithelial tumor and malignant germ cell tumor is also rare, with most cases composed of endometrioid adenocarcinoma and yolk sac tumor.
  • Ovarian MMMT with malignant neuroectodermal components resembling immature teratoma is extremely rare.
  • We report a case of teratoid carcinosarcoma of the ovary occurring in a 40-year-old female.
  • The resected tumor measuring over 20 cm in diameter consisted of cystic and solid components and was very fragile.
  • Microscopic examination showed a heterogenous mixed tumor composed of malignant epithelial, malignant mesodermal and malignant neuroectodermal components.
  • There was no tumor immunoreactivity to alpha-fetoprotein, carcinoembryonic antigen, human chorionic gonadotropin, and inhibin.
  • In spite of aggressive combination chemotherapy and three times of laparotomy, the patient died of disease 3 years 10 months after the initial treatment.
  • This quite rare ovarian tumor closely resembled nasopharyngeal tumors described as 'teratoid carcinosarcoma' is biologically aggressive.
  • Further cases need to be accumulated to make diagnosis and to determine a successful treatment modality.
  • [MeSH-major] Carcinosarcoma / pathology. Mixed Tumor, Mullerian / pathology. Ovarian Neoplasms / pathology. Teratoma / pathology
  • [MeSH-minor] Adult. Fatal Outcome. Female. Humans. Ovary / pathology. Ovary / surgery

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20666968.001).
  • [ISSN] 1447-0756
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


8. Hubalek M, Ramoni A, Mueller-Holzner E, Marth C: Malignant mixed mesodermal tumor after tamoxifen therapy for breast cancer. Gynecol Oncol; 2004 Oct;95(1):264-6
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed mesodermal tumor after tamoxifen therapy for breast cancer.
  • BACKGROUND: The risk of tamoxifen related endometrial neoplasm has been confirmed by multiple studies.
  • Especially rare endometrial tumors seem to develop more frequently under tamoxifen therapy.
  • A recent analysis showed a substantially higher risk for malignant mixed mesodermal tumor (MMMT; designated in the WHO classification of female genital tract neoplasms as carcinosarcoma) in association with tamoxifen intake.
  • CASE: We are reporting a case of a 40-year-old multiparous premenopausal woman who received tamoxifen 20 mg daily for 2 years after the surgical treatment of breast cancer and subsequent adjuvant chemotherapy.
  • Two years after initiation of tamoxifen treatment, the patient developed an MMMT of the uterus.
  • Unfortunately, she developed a local recurrence of her breast cancer in 2003.
  • After surgical treatment, she is currently being treated with anastrozole.
  • CONCLUSION: We are reporting a rare case of a premenopausal patient who developed a MMMT within short time of tamoxifen exposure for stage I breast cancer.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Mixed Tumor, Mesodermal / chemically induced. Neoplasms, Second Primary / chemically induced. Tamoxifen / adverse effects. Uterine Neoplasms / chemically induced
  • [MeSH-minor] Adult. Female. Humans

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15385144.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


9. Johann S, Mueller MD: [Follow-up after malignant tumours of the uterus (cancer of the uterine corpus / cervical cancer)]. Ther Umsch; 2008 Jun;65(6):341-6
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Follow-up after malignant tumours of the uterus (cancer of the uterine corpus / cervical cancer)].
  • Malignant uterine tumours can affect the corpus or the cervix.
  • Cervical cancer presents an own entitity, regarding both histology and therapeutic options.
  • Endometrial cancer is the most common genital malignoma in Northern Europe and North America.
  • Histologically, the endometrial cancer can be subdivided in two groups: type I is hormonal sensitive and well differentiated, type II represents an undifferenciated aggressive tumour with poor prognosis.
  • First choice in therapy is stage related surgery.
  • Surgery is only indicated up to stage IIA, advanced stages should be treated by radio-chemotherapy.
  • Intention is the detection of the curable local relapse.
  • [MeSH-major] Aftercare / methods. Neoplasm Recurrence, Local / diagnosis. Neoplasms, Second Primary / diagnosis. Postoperative Complications / diagnosis. Uterine Cervical Neoplasms / surgery. Uterine Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy. Evidence-Based Medicine. Female. Humans. Neoplasm Staging. Positron-Emission Tomography. Prognosis. Tomography, X-Ray Computed


10. Pratt BL, Greene FL: Role of laparoscopy in the staging of malignant disease. Surg Clin North Am; 2000 Aug;80(4):1111-26

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of laparoscopy in the staging of malignant disease.
  • Together with the fervor and benefits afforded by laparoscopic therapeutic interventions in the management of patients with benign disease and the diagnostic usefulness in blunt trauma and abdominal pain, awareness has been rekindled regarding the advantages of laparoscopy for the staging of abdominal malignancy.
  • Similarly, it is hoped that the use of systemic chemotherapy will achieve better specificity in cell destruction in patients identified laparoscopically to have uncontained disease in the abdominal cavity.
  • 7), both diagnostic and therapeutic, in the management of patients with abdominal malignancy will be limited only by the creativity and expertise of physicians and instrument makers.
  • [MeSH-major] Laparoscopy. Neoplasm Staging / methods. Neoplasms / pathology
  • [MeSH-minor] Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Esophageal Neoplasms / pathology. Esophageal Neoplasms / surgery. Female. Genital Neoplasms, Female / pathology. Genital Neoplasms, Female / surgery. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Lymphoma / pathology. Lymphoma / surgery. Palliative Care. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery. Prognosis. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10987027.001).
  • [ISSN] 0039-6109
  • [Journal-full-title] The Surgical clinics of North America
  • [ISO-abbreviation] Surg. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 82
  •  go-up   go-down


11. Milojkovic M, Hrgovic Z, Hrgovic I, Jonat W, Maass N, Buković D: Significance of CA 125 serum level in discrimination between benign and malignant masses in the pelvis. Arch Gynecol Obstet; 2004 Mar;269(3):176-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of CA 125 serum level in discrimination between benign and malignant masses in the pelvis.
  • AIM: Our aim was to confirm that preoperative CA 125 serum level can be useful for discrimination between benign and malignant masses in the pelvis.
  • METHODS: Preoperative CA 125 serum level was analyzed retrospectively in 121 patients who had surgery because of a malignant ovarian tumor and in 91 patients with benign masses in the pelvis.
  • The cutoff serum level CA 125 between benign and malignant masses in the pelvis was 35 and 65 IU/ml.
  • RESULTS: Of those patients with a malignant ovarian tumor, 65.3% had menopause whereas only 31.5% of those with a benign tumor did so.
  • The average age of the patients with a malignant tumor was 54.2 years and of those with a benign tumor 46.8 years.
  • The preoperative CA 125 serum level was higher than 35 IU/ml in 80.2% and higher than 65 IU/ml in 72.7% of all analyzed patients with a malignant tumor, whereas it was 23.9% and 9.8% respectively in patients with a benign mass.
  • After therapy the CA 125 serum level dropped below 35 IU/ml in 70.8% and after three chemotherapy courses in 78.1%.
  • A CA 125 level less than 35 IU/ml was achieved by therapy in 84.2% patients with an early stage disease (I/II) and in 62.1% in advanced stages (III/IV).
  • CONCLUSION: . Preoperative determination of CA 125 is a very useful method to discriminate between benign and malignant masses in the pelvis.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Genital Diseases, Female / blood
  • [MeSH-minor] Cystadenocarcinoma, Mucinous / blood. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Mucinous / surgery. Cystadenocarcinoma, Serous / blood. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Female. Humans. Middle Aged. Neoplasm Staging. Ovarian Neoplasms / blood. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Predictive Value of Tests. Preoperative Care. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14557888.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


12. Müller H, Nakchbandi V: Cytoreductive surgery plus intraperitoneal hyperthermic perfusion is an effective treatment for metastasized malignant mixed mesodermal tumours (MMMT)--report of six cases. Eur J Surg Oncol; 2004 Jun;30(5):573-7
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery plus intraperitoneal hyperthermic perfusion is an effective treatment for metastasized malignant mixed mesodermal tumours (MMMT)--report of six cases.
  • BACKGROUND: Malignant mixed mesodermal tumours (MMMT) of the female genital tract are rare and heterogeneous malignancies that impart grim prognosis.
  • These tumours are characterized by an admixture of malignant epithelial and stromal elements comprising carcinomatous and sarcomatous neoplastic cells.
  • Due to its rarity, there is no agreement on the best treatment strategy in women with metastasized MMMT.
  • METHODS: Six women (mean age 59 years) with metastasized MMMT defined to the peritoneal cavity have been treated by cytoreductive surgery plus hyperthermic peritoneal perfusion plus postoperative adjuvant chemotherapy.
  • All patients have been pre-treated by surgery for primary tumour and one by systemic chemotherapy.
  • As adjuvant treatment CDDP 40 mg/m2/dl, Mitomycin 7 mg/md2/dl and Ifosfamid 100 mg/kg 24 h/dl was applicated via intraaortic catheter three times with a treatment free interval of 3 weeks.
  • Four patients are without evidence of disease after 2, 4, 14 and 19 months, whereas one patient developed liver metastases after 9 months still treated by systemic chemotherapy.
  • CONCLUSION: Complete cytoreduction plus hyperthermic peritoneal perfusion plus adjuvant chemotherapy seems to be an effective treatment for recurrent or metastasized MMMT.
  • Further studies have to define the value of this new treatment strategy for this rare tumour entity.
  • [MeSH-major] Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced. Mixed Tumor, Malignant / secondary. Mixed Tumor, Malignant / therapy. Mixed Tumor, Mesodermal / secondary. Mixed Tumor, Mesodermal / therapy. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Germany. Humans. Ifosfamide / administration & dosage. Laparotomy. Liver / pathology. Middle Aged. Mitomycin / administration & dosage. Neoplasm Recurrence, Local / therapy. Neoplasm Staging. Peritoneal Cavity / pathology. Treatment Outcome. Women's Health

  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Surg Oncol. 2005 Feb;31(1):111-2 [15642436.001]
  • (PMID = 15135489.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 50SG953SK6 / Mitomycin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


13. Pusceddu S, Bajetta E, Buzzoni R, Carcangiu ML, Platania M, Del Vecchio M, Ditto A: Primary uterine cervix melanoma resembling malignant peripheral nerve sheath tumor: a case report. Int J Gynecol Pathol; 2008 Oct;27(4):596-600
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary uterine cervix melanoma resembling malignant peripheral nerve sheath tumor: a case report.
  • A rare variant of malignant melanoma (MM) of the uterine cervix that mimics a malignant peripheral nerve sheath tumor (MPNST) is described.
  • A 43-year-old white woman was admitted to the hospital complaining of genital discharge and vaginal bleeding.
  • Neoadjuvant chemotherapy and total abdominal hysterectomy and bilateral salpingo-ovariectomy plus pelvic lymphadenectomy were performed, and the diagnosis was MPNST, FIGO IIB.
  • A pathological review was obtained in our institution by a gynecological pathologist, who defined the primary neoplasm in the cervix as an MM, with a pattern of growth histologically simulating an MPNST, metastatic to the vagina.
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Histocytochemistry. Humans


14. O'Toole SA, Sheppard BL, McGuinness EP, Gleeson NC, Yoneda M, Bonnar J: The MTS assay as an indicator of chemosensitivity/resistance in malignant gynaecological tumours. Cancer Detect Prev; 2003;27(1):47-54
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The MTS assay as an indicator of chemosensitivity/resistance in malignant gynaecological tumours.
  • The aim of this study was to use the (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) (MTS) assay to determine the response of 17 endometrial and 27 cervical tumours to cytotoxic drugs.
  • Cells were incubated with chemotherapy drugs.
  • The MTS cytotoxicity assay was carried out to ascertain the response to the drugs and correlated retrospectively to the clinical outcome.
  • Tumours of similar stage and grade displayed heterogeneity in their responses to the drugs.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Drug Resistance, Neoplasm. Genital Neoplasms, Female / drug therapy. Toxicity Tests / methods
  • [MeSH-minor] Cell Survival / drug effects. Cells, Cultured. Cisplatin / pharmacology. Drug Screening Assays, Antitumor / methods. Drug Therapy, Combination. Endometrial Neoplasms / drug therapy. Female. Fluorouracil / pharmacology. Humans. Neoplasm Staging. Paclitaxel / pharmacology. Retrospective Studies. Tetrazolium Salts. Topotecan / pharmacology. Treatment Outcome. Uterine Cervical Neoplasms / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 International Society for Preventive Oncology
  • (PMID = 12600417.001).
  • [ISSN] 0361-090X
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Tetrazolium Salts; 7M7YKX2N15 / Topotecan; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


15. Leblanc E, Narducci F, Ferron G, Querleu D: Indications and teaching of fertility preservation in the surgical management of gynecologic malignancies: European perspective. Gynecol Oncol; 2009 Aug;114(2 Suppl):S32-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Young women affected by a malignant tumor have to cope, after the announcement of diagnosis, with the treatment and its secondary effects.
  • Especially in pelvic tumors, treatments are more or less mutilating, either by a direct surgical resection of pelvic organs or by destruction of their functioning after chemotherapy or radiation therapy.
  • It is important for them to be aware not only of the surgical techniques currently available to preserve fertility, but as well of their indications and limits, according to the tumor type or its treatment.
  • [MeSH-major] Fertility. Genital Neoplasms, Female / surgery. Gynecologic Surgical Procedures / education. Gynecologic Surgical Procedures / methods
  • [MeSH-minor] Female. Humans. Laryngoscopy / methods. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19573704.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 61
  •  go-up   go-down


16. Wei W, Shen K: [Photodynamic therapy and its application in gynecologic oncology]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Aug;25(4):484-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Photodynamic therapy and its application in gynecologic oncology].
  • While photodynamic therapy is applied on neoplasm, photosensitisers tend to accumulate in neoplastic tissues.
  • With appropriate wavelength light, it causes photochemical reaction and destructs neoplastic tissues.
  • Its better selection for tumor tissue with effective photochemical reaction, and lower side effect make it widespread application in gynecologic oncology.
  • At present, photodynamic therapy has been used in diagnosing and treating lower genital tract carcinoma in situ, and advanced malignant tumor such as vulval and ovarian carcinoma.
  • [MeSH-major] Hematoporphyrin Derivative / therapeutic use. Ovarian Neoplasms / drug therapy. Photochemotherapy. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Female. Genital Neoplasms, Female / drug therapy. Hematoporphyrin Photoradiation. Humans. Photosensitizing Agents / therapeutic use

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12974099.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 68335-15-9 / Hematoporphyrin Derivative
  • [Number-of-references] 16
  •  go-up   go-down


17. Sauer G, Deissler H: Angiogenesis: prognostic and therapeutic implications in gynecologic and breast malignancies. Curr Opin Obstet Gynecol; 2003 Feb;15(1):45-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenesis: prognostic and therapeutic implications in gynecologic and breast malignancies.
  • PURPOSE OF REVIEW: Growth, invasion and metastasis of malignant tumors depend on angiogenesis, which is therefore considered an attractive therapeutic target and indicator of clinical outcome.
  • In addition, many studies point to a role of angiogenesis as a predictor of response to both antiangiogenic and conventional chemotherapy or radiotherapy.
  • Novel therapeutic approaches with inhibitors of angiogenesis are promising, although the adaptation of most experimentally proven approaches to clinical practice appears to be a laborious process.
  • Furthermore, for an appropriate clinical evaluation of these drugs, newly defined endpoints of treatment and new monitoring systems reflecting their mode of action and the anticipated biological effects are required.
  • Antiangiogenic therapy will most likely play an important role in future clinical management of malignant diseases.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Breast Neoplasms / blood supply. Breast Neoplasms / drug therapy. Genital Neoplasms, Female / blood supply. Genital Neoplasms, Female / drug therapy. Neovascularization, Pathologic / drug therapy
  • [MeSH-minor] Angiostatins. Biopsy, Needle. Female. Humans. Neoplasm Staging. Peptide Fragments / therapeutic use. Plasminogen / therapeutic use. Prognosis. Randomized Controlled Trials as Topic. Risk Assessment. Sensitivity and Specificity. Thrombospondins / therapeutic use. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12544501.001).
  • [ISSN] 1040-872X
  • [Journal-full-title] Current opinion in obstetrics & gynecology
  • [ISO-abbreviation] Curr. Opin. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Peptide Fragments; 0 / Thrombospondins; 86090-08-6 / Angiostatins; 9001-91-6 / Plasminogen
  • [Number-of-references] 32
  •  go-up   go-down


18. Ramirez PT, Wolf JK, Malpica A, Deavers MT, Liu J, Broaddus R: Wolffian duct tumors: case reports and review of the literature. Gynecol Oncol; 2002 Aug;86(2):225-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Female adnexal tumors of probable wolffian origin are a distinctive epithelial neoplasm arising from the remnants of the mesonephric duct.
  • Although generally considered a tumor of low malignant potential, these tumors can recur.
  • The pathologic findings were consistent with a female adnexal tumor of probable wolffian origin.
  • The recurrence was confirmed at laparotomy and tumor debulking was performed.
  • Four months later the patient suffered a second recurrence and is currently undergoing treatment with systemic therapy. (2) A 71-year-old Caucasian woman who had undergone exploratory laparotomy and tumor reductive surgery for a female adnexal tumor of probable wolffian duct origin was seen for routine evaluation 1 year after her surgery.
  • Her computed tomography scan revealed possible evidence of recurrence.
  • CONCLUSION: Most female adnexal tumors of wolffian origin behave in a benign fashion.
  • Surgical excision by total abdominal hysterectomy and bilateral salpingo-oophorectomy at the time of diagnosis may be the best recommended mode of therapy.
  • The role of adjuvant radiation therapy or chemotherapy remains questionable.
  • [MeSH-major] Genital Neoplasms, Female. Wolffian Ducts
  • [MeSH-minor] Adult. Aged. Female. Humans. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12144833.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 22
  •  go-up   go-down


19. Semczuk A, Skomra D, Rybojad P, Jeczeń R, Rechberger T: Endometrial carcinoma with pleural metastasis: A case report. Acta Cytol; 2006 Nov-Dec;50(6):697-700

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: There have been a limited number of studies giving the incidence of pleural metastasis from female genital tract tumors.
  • CASE: An unusual case occurred of recurrent pleural malignant effusion associated with disseminated serous papillary endometrial adenocarcinoma (EC).
  • Treatment of the pleural malignant effusion consisted of thoracotomy with partial decortication, systemic chemotherapy and radiotherapy.
  • CONCLUSION: Although the pleura is a rare site of widespread EC, one should recognize the possibility of pleural spread from female genital tract neoplasms presenting with associated symptoms.
  • Cytopathologic examination of the pleural effusion and the finding ofcarcinoma cells mandate an investigation for the primary site of the neoplasm by a multidisciplinary group.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Combined Modality Therapy. Fatal Outcome. Female. Humans. Hysterectomy. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17152287.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


20. Lin O: Challenges in the interpretation of peritoneal cytologic specimens. Arch Pathol Lab Med; 2009 May;133(5):739-42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: The presence of malignant cells in peritoneal washings leads to classification as International Federation of Gynecology and Obstetrics stage IC or higher in ovarian carcinomas and at least International Federation of Gynecology and Obstetrics stage IIIA in endometrial carcinomas.
  • Malignant cells might be few in number and might be unrecognized among a large population of mesothelial cells and/or macrophages, or reactive mesothelial cells might be misinterpreted as neoplastic cells leading to unnecessary chemotherapy.
  • [MeSH-major] Adenocarcinoma / pathology. Ascitic Fluid / pathology. Cytodiagnosis / methods. Genital Neoplasms, Female / pathology. Peritoneal Lavage
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Humans. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19415948.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 63
  •  go-up   go-down


21. Varras M, Akrivis Ch, Demou A, Hadjopoulos G, Stefanaki S, Antoniou N: Primary small-cell carcinoma of the endometrium: clinicopathological study of a case and review of the literature. Eur J Gynaecol Oncol; 2002;23(6):577-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Small-cell carcinomas are almost always primary in the lungs and are highly malignant.
  • These tumors may also occur in the female genital tract.
  • This tumor may exhibit evidence of neuroendocrine differentiation and has a high propensity for systemic spread and poor prognosis.
  • CASE: A 55-year-old postmenopausal woman with primary small-cell carcinoma of the endometrium, FIGO stage Ib, underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy and sampling node biopsies of the parametrial spaces, followed by adjuvant combined chemotherapy.
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12556112.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 26
  •  go-up   go-down


22. Petru E, Pasterk C, Reich O, Obermair A, Winter R, Breitenecker G: Small-cell carcinoma of the uterus and the vagina: experience with ten patients. Arch Gynecol Obstet; 2005 Apr;271(4):316-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Small cell carcinomas (small-CCs) of the uterine cervix are rare and highly malignant neoplasms.
  • Patients tend to develop distant metastasis early and thus are potential candidates for systemic therapy.
  • Eight patients underwent radical surgery, 7 of whom also received chemotherapy.
  • She had received six courses of dose-intensive platinum chemotherapy after radical surgery.
  • All three patients with small-CC of the uterine corpus or vagina developed recurrence within the first year after diagnosis.
  • Of the 7 patients who received chemotherapy, 5 developed progressive or recurrent disease in the paraaortic region (n=2), peritoneum (n=1), liver (n=1), or pelvis (n=1).
  • CONCLUSION: These results confirm the particularly unfavorable prognosis of patients with small-CC of the genital tract.
  • The optimal treatment for these patients most probably including concurrent chemo-radiotherapy remains to be defined.
  • [MeSH-major] Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / therapy. Uterine Neoplasms / diagnosis. Uterine Neoplasms / therapy. Vaginal Neoplasms / diagnosis. Vaginal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Gynecologic Surgical Procedures. Humans. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Radiotherapy. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15197564.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


23. Zimny M, Siggelkow W: Positron emission tomography scanning in gynecologic and breast cancers. Curr Opin Obstet Gynecol; 2003 Feb;15(1):69-75
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positron emission tomography scanning in gynecologic and breast cancers.
  • PURPOSE OF REVIEW: Positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose represents a noninvasive functional imaging modality that is based on metabolic characteristics of malignant tumors.
  • RECENT FINDINGS: In breast cancer, positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose is more accurate than conventional methods for the staging of distant metastases, enables early assessment of treatment response in patients undergoing primary chemotherapy.
  • The diagnostic accuracy for axillary lymph node staging depends on the tumor load of the lymph nodes.
  • False negative findings in well differentiated adenocarcinoma and borderline lesions as well as false positive findings in benign conditions limit the role of positron emission tomography scanning for the differential diagnosis of adnex tumors.
  • SUMMARY: Positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose reveals unique information about tumor metabolism in gynecologic malignancies and breast cancer.
  • It may become the method of choice for the early assessment of treatment response in breast cancer and the detection of recurrent disease in ovarian cancer.
  • [MeSH-major] Breast Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Genital Neoplasms, Female / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Tomography, Emission-Computed / methods
  • [MeSH-minor] Female. Humans. Neoplasm Staging. Predictive Value of Tests. Prognosis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12544505.001).
  • [ISSN] 1040-872X
  • [Journal-full-title] Current opinion in obstetrics & gynecology
  • [ISO-abbreviation] Curr. Opin. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 62
  •  go-up   go-down


24. Olejek A, Damasiewicz-Bodzek A, Bodzek P, Wielkoszyński T, Zamłyński J, Stołtny P, Skutil M: Concentrations of antibodies against heat shock protein 27 in the sera of women with ovarian carcinoma. Int J Gynecol Cancer; 2009 Dec;19(9):1516-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Heat shock proteins (Hsp) are highly expressed in many malignant human tumors, including tumors of the genital tract.
  • The aim of this work was to study the concentrations of anti-Hsp27 immunoglobulin G antibodies in the sera of women with ovarian cancer at different clinical stages and with different histopathological types of this cancer.
  • The mean concentrations of the anti-Hsp27 antibodies in the patients with ovarian carcinoma were not significantly different in relation to the histological type of the cancer.
  • The use of chemotherapy as a primary anticancer treatment in ovarian carcinoma did not cause a significant decrease in the concentration of anti-Hsp27 antibodies.
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / blood. Case-Control Studies. Disease Progression. Early Detection of Cancer. Female. Humans. Middle Aged. Neoplasm Staging. Osmolar Concentration

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19955928.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / HSP27 Heat-Shock Proteins
  •  go-up   go-down


25. Bondavalli C, Dall'Oglio B, Schiavon L, Luciano M, Guatelli S, Parma P, Galletta V: [Complications of urinary diversion after radiotherapy]. Arch Ital Urol Androl; 2003 Mar;75(1):10-3
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary radiation therapy may be recommended for patients with invasive bladder cancer, gynecological or prostatic cancer.
  • When complications occur or in case of malignant recurrence, urinary diversion may be the best chance to restore an acceptable quality of life.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12741338.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ITA
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 24
  •  go-up   go-down


26. Gallardo A, Prat J: Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55 cases challenging the existence of adenofibroma. Am J Surg Pathol; 2009 Feb;33(2):278-88
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mullerian adenosarcomas are rare mixed tumors of low malignant potential that occur mainly in the uterus and also in extrauterine locations.
  • Treatment was known in 50 patients: 10 had polypectomy, 1 cone biopsy, and 39 hysterectomy, which was accompanied by bilateral salpingo-oophorectomy in 24 and lymphadenectomy in 4.
  • Five patients had radiotherapy and 2 of them had chemotherapy.
  • The tumor of the fallopian tube was stage IC, and the tumors of the vagina and recto-uterine pouch were confined to their site of origin.
  • Six developed metastases and 5 of them died of tumor.
  • The finding of such cases, which raises the controversy of whether or not adenofibroma exists as a tumor entity, prompted us to make a comparative immunohistochemical analysis of 23 typical adenosarcomas, 8 adenosarcomas with sarcomatous overgrowth, and 29 benign and malignant related lesions, including 7 clinically benign adenofibromas.
  • Adenosarcomas with sarcomatous overgrowth showed strong immunoreaction for Ki-67 and p53 and loss of CD10 and progesterone receptors immunostaining; in contrast, the immunoreaction for these tumor markers in typical adenosarcomas without sarcomatous overgrowth was similar to that of adenofibromas associated with favorable outcome and other benign lesions such as endometrial polyps and endometriosis.
  • [MeSH-major] Adenofibroma / pathology. Adenosarcoma / pathology. Genital Neoplasms, Female / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Mitotic Index. Neoplasm Staging. Tissue Array Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18941402.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down






Advertisement